Evaluating Gut Microbiome As A Biomarker Of Pathological Complete Response In
Patients With Early Triple Negative Breast Cancer - A Pilot Study (TCC)
The purpose of the study is to is to obtain information on the microbiome – bacteria and other microbes living all over the outside and inside the human body. Specifically, investigators would like to know more about the gut microbiome of participants with breast cancer who plan to receive chemotherapy at Moffitt Cancer Center
In patients with non-metastatic triple negative breast cancer, eligible for neoadjuvant chemotherapy+/- immunotherapy:
1. Characterize gut microbiota and microbial metabolite of patients starting standard neoadjuvant treatment.
2. Compare differences in gut microbiota/metabolite between pathological complete responders vs non-responders.
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub